In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RedHill Biopharma Ltd.

www.redhillbio.com

Latest From RedHill Biopharma Ltd.

Keeping Track: US FDA Approves Pfizer’s Vyndaqel, Jacobus’ Ruzurgi, But Nixes Acacia’s Barhemsys Again

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Approvals

BIO-Europe Spring 2019: RedHill Preps NDA Submission For Antibiotic Talicia

Gilead Raday, chief operating officer of RedHill Biopharma, talks to Lucie Ellis, executive editor of In Vivo, about recently published late-stage data and next steps for its antibiotic asset, Talicia (RHB-105), for the treatment of Helicobacter pylori infection. 

Clinical Trials Infectious Diseases

Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

RedHill Unveils Plans For Pivotal Phase III Study For Crohn’s Therapy

RedHill Biopharma’s study results for its novel antibiotic approach to Crohn’s disease has left the company with some unanswered questions, despite hitting its endpoints in a recent Phase III study. Its COO, Gilead Raday, talks to Scrip about the next steps for the study.

Gastrointestinal Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • RedHill Biopharma Ltd.
  • Senior Management
  • Dror Ben-Asher, CEO
    Micha Ben Chorin, CFO
    Adi Frish, SVP, Bus. Dev & Licensing
    Reza Fathi , PhD, SVP, R&D
    Gilead Raday, COO
    June S Almenoff, MD, PhD, CSO
  • Contact Info
  • RedHill Biopharma Ltd.
    Phone: (972) 3 541 3131
    21 Ha’arba’a St.
    Tel-Aviv, 64739
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register